GH Research News

GH Research Analyst Ratings

BenzingaMar 4 13:06 ET

Buy Rating for GH Research: Promising Clinical Trials and Strategic Intellectual Property Advances

TipRanksMar 4 11:36 ET

GH Research Analyst Ratings

BenzingaMar 1 11:49 ET

Buy Rating Justified by GH Research's Promising Clinical Trials and Strong Financial Health

TipRanksMar 1 01:36 ET

Optimistic Outlook for GH Research With Progressing Phase 2 Trials and Strong IP Portfolio Reinforcing Buy Rating

TipRanksJan 22 12:57 ET

GH Research Analyst Ratings

BenzingaJan 18 06:13 ET

Stifel Maintains Buy on GH Research, Lowers Price Target to $18

BenzingaDec 18, 2023 09:31 ET

GH Research Analyst Ratings

BenzingaDec 18, 2023 09:28 ET

GH Research Analyst Ratings

BenzingaNov 14, 2023 11:11 ET

Analysts Offer Insights on Technology Companies: Inuvo (INUV) and GH Research (GHRS)

TipRanksNov 10, 2023 14:50 ET

GH Research Earns 'Buy' Rating: Promising Progress, Proactive Approach, and Solid Financial Standing

TipRanksNov 10, 2023 00:35 ET

Positive Outlook for GH Research Despite FDA's Clinical Hold: An Analysis of GH001's Trials and Prospects

TipRanksOct 3, 2023 14:15 ET

GH Research: Temporary FDA Setback and Promising European Trials Bolster Buy Rating

TipRanksOct 2, 2023 00:15 ET

H.C. Wainwright Sticks to Their Buy Rating for GH Research (GHRS)

TipRanksAug 24, 2023 12:15 ET

GH Research (GHRS) Gets a Buy From JMP Securities

TipRanksAug 23, 2023 10:45 ET

H.C. Wainwright Keeps Their Buy Rating on GH Research (GHRS)

TipRanksJul 6, 2023 11:35 ET

JMP Securities Adjusts Price Target on GH Research to $49 From $46, Maintains Market Outperform Rating

MT NewswiresMay 12, 2023 07:11 ET

HC Wainwright & Co. Reiterates Buy on GH Research, Maintains $45 Price Target

BenzingaMay 12, 2023 06:36 ET

JMP Securities Maintains Outperform on GH Research, Raises Price Target to $49

BenzingaMay 12, 2023 06:18 ET

H.C. Wainwright Remains a Buy on GH Research (GHRS)

TipRanksMay 12, 2023 06:15 ET